List of Studies ( Metabolite:18-HETE)
Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
---|---|---|---|---|---|---|---|
ST001680 | AN002738 | Metabolome of NAFLD in high fat diet mouse model | Liver | Mouse | Fatty liver disease | Weill Cornell Medicine | Abundance |
ST002455 | AN004005 | Organism-Wide Analysis of Sepsis Reveals Mechanisms of Systemic Inflammation | Blood | Mouse | Sepsis | University of Chicago | intensity |
ST001951 | AN003176 | Quantification of ω-3 fatty acids and their derivatives in lungs from hypoxia-induced pulmonary hypertension (PH) mice. | Lung | Mouse | Pulmonary hypertension | University of Tokyo | ng/mg tissue |
ST000004 | AN000004 | Lipidomics studies on NIDDK / NIST human plasma samples | Blood | Human | LIPID MAPS | nM | |
ST000916 | AN001491 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma | Blood | Human | Fatty liver disease | LIPID MAPS | nM |
ST003050 | AN005001 | Plasma instead of serum avoids critical confounding of clinical metabolomics studies by platelets (Part 1) | Blood | Human | University of Vienna | normalized AUC | |
ST001206 | AN002008 | Effects of cold exposure on serum lipidomic in mice | Blood | Mouse | Joslin Diabetes Center - Harvard Medical School | Peak area | |
ST001207 | AN002009 | Lipidomics in the serum of cold exposed mice treated with 12-LOX inhibitor LOXBlock-1 | Blood | Mouse | Joslin Diabetes Center - Harvard Medical School | Peak area | |
ST001213 | AN002024 | Serum lipidomic profile of cold-exposed Ucp1cre/12-LOX KO mice | Blood | Mouse | Joslin Diabetes Center - Harvard Medical School | Peak area | |
ST001214 | AN002025 | Lipidommics in the serum of human subjects | Blood | Human | Joslin Diabetes Center - Harvard Medical School | Peak area | |
ST001215 | AN002026 | Effect of Mirabegron Treatment on serum lipidome | Blood | Human | Joslin Diabetes Center - Harvard Medical School | Peak area | |
ST000915 | AN001485 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver | Liver | Human | Fatty liver disease | LIPID MAPS | pmol/mg |